VGH Solutions Feels Pain In US Review For Basing OTC Device Ad Claims On Canada’s Approval
NAD advises VGH Solutions to pull pain relief claims and statements that am OTC device with FDA 510(k) clearance treats conditions including neuropathy. The firm offered studies and a Health Canada statement listing indications for the device to support claims not part of the US approved indication.
You may also be interested in...
The Capillus82 Hair Regrowth Laser Cap may be "substantially equivalent" to the manufacturer's Capillus272 Pro device, based on FDA's 510(k) clearance, but NAD says hair-growth clinical findings from that "predicate" device cannot serve to substantiate claims for the untested Capillus82. The case illustrates complexities in the medical device segment, which increasingly is of interest to cosmetics companies.
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.
National Advertising Review Board says P&G’s #1” claim in a shield-shaped logo on Oral-B Precision Clean Interdental Picks package fronts “is adequately connected to the explanatory information," which states “from the makers of the #1 dentist recommended floss brand.”